Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539923 | 0.83 | HCAR2 (0.42) | CDK1CDK4CCNE1CDK2CCNB2 | |
| SCHEMBL948557 | 0.82 | CDC7 (0.47) | CDC7DBF4CDK1CDK4CCNE1 | |
| Hydrochloric Acid SCHEMBL1540153 | 0.82 | HCAR2 (0.41) | CDK1CDK4CCNE1CDK2CCNB2 | |
| SCHEMBL1540152 | 0.82 | CCNE2 (0.39) | CDK1CDK4CCNE1CDK2CCNB2 | |
| SCHEMBL14185028 | 0.79 | CDC7 (0.51) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL16113496 | 0.77 | CCNE1 (0.60) | CDC7DBF4CDK1CDK4CCNE1 | |
| SCHEMBL12291072 | 0.77 | CDC7 (0.55) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL21445175 | 0.76 | CDC7 (0.49) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL1539965 | 0.76 | ALDH1A1 (0.61) | ALDH1A1HPGDMAPTKDM4EGAA | |
| SCHEMBL23334312 | 0.76 | CDC7 (0.54) | CDC7DBF4HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-9382219-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| EP-2918584-A1 | Process and intermediates for the preparation of dasatinib | Cerbios-Pharma S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-11 | — | — | US | disclosed |
| US-8993567-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-6979694-B2 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | DAS JAGABANDHU | 2005-11-24 | — | — | US | disclosed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | CDC7 175/4885DBF4 2113/4885HDAC3 4181/4885 |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | LCK, SSB, JAK1 | CDC7 160/4885DBF4 1968/4885HDAC3 2863/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | CDC7 175/4885DBF4 2113/4885HDAC3 4181/4885 |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | ABL1, SRC, ABL2 | CDC7 516/4885DBF4 2593/4885HDAC3 3563/4885 |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | CDC7 383/4885DBF4 2334/4885HDAC3 938/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | CDC7 175/4885DBF4 2113/4885HDAC3 4181/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | CDC7 658/4885DBF4 2425/4885HDAC3 386/4885 |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | CDC7 175/4885DBF4 2113/4885HDAC3 4181/4885 |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | JAK2, JAK1, TYK2 | CDC7 935/4885DBF4 3437/4885HDAC3 1949/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | CDC7 175/4885DBF4 2113/4885HDAC3 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.